MARKET

SABSW

SABSW

SAB BIOTHERAPEUTICS INC
NASDAQ
0.0161
0.0000
0.00%
Opening 12:14 05/20 EDT
OPEN
0.0160
PREV CLOSE
0.0161
HIGH
0.0179
LOW
0.0160
VOLUME
11.00K
TURNOVER
--
52 WEEK HIGH
0.1800
52 WEEK LOW
0.0150
MARKET CAP
--
P/E (TTM)
-0.0112
1D
5D
1M
3M
1Y
5Y
1D
This QuickLogic Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
Benzinga · 12h ago
SAB Biotherapeutics Price Target Announced at $11.00/Share by Jefferies
Dow Jones · 12h ago
Jefferies Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $11
Benzinga · 12h ago
Analysts’ Top Healthcare Picks: Hims & Hers Health (HIMS), SAB Biotherapeutics (SABS)
TipRanks · 15h ago
SAB Biotherapeutics initiated with a Buy at Jefferies
TipRanks · 15h ago
Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (HIMS) and SAB Biotherapeutics (SABS)
TipRanks · 15h ago
Weekly Report: what happened at SABS last week (0511-0515)?
Weekly Report · 2d ago
Analysts Conflicted on These Healthcare Names: Qiagen (QGEN), SAB Biotherapeutics (SABS) and Moderna (MRNA)
TipRanks · 6d ago
More
About SABSW
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.

Webull offers SAB Biotherapeutics Inc stock information, including NASDAQ: SABSW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SABSW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SABSW stock methods without spending real money on the virtual paper trading platform.